Stock Events

Stock Events

Oramed Pharmaceuticals 

$3.83
63
-$0.04-1.03% Today

Statistics

Day High
3.92
Day Low
3.82
52W High
5.01
52W Low
1.98
Volume
3,689,140
Avg. Volume
-
Mkt Cap
152.44M
P/E Ratio
1.4
Dividend Yield
6.46%
Dividend
0.25

Upcoming

18
JAN 27
Dividend Ex
Estimated
 
28
JAN 27
Dividend Payment
Estimated
 
17
JAN 28
Dividend Ex
Estimated
 
27
JAN 28
Dividend Payment
Estimated
 

Dividends

6.46%Dividend Yield
Jan 26
$0.25
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.48
-0.27
-0.06
0.15
Expected EPS
0.15
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-38.12MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORMP. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap194.35B
Novo Nordisk is a leading global healthcare company that develops diabetes care products, directly competing with Oramed's oral insulin capsule.
Mannkind
MNKD
Mkt Cap1.13B
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for diabetes, such as Afrezza, competing in the diabetes management space.
Sanofi
SNY
Mkt Cap105.92B
Sanofi is a multinational pharmaceutical company that offers a range of diabetes solutions, including insulin products, competing in the same therapeutic area as Oramed.
Lilly(Eli) &
LLY
Mkt Cap1.01T
Eli Lilly and Company is a global healthcare leader that develops a wide range of pharmaceutical products, including treatments for diabetes, directly competing with Oramed's products.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca is a global, science-led biopharmaceutical business that has a significant portfolio of diabetes treatments, competing in the same market as Oramed.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol-Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines, including for diabetes, which puts it in competition with Oramed.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. offers a broad range of diabetes treatments, including oral medications, directly competing with Oramed's oral insulin product.
Tandem Diabetes Care
TNDM
Mkt Cap1.33B
Tandem Diabetes Care, Inc. designs, develops, and commercializes products for people with insulin-dependent diabetes, competing in the broader diabetes care market.
Insulet
PODD
Mkt Cap10.37B
Insulet Corporation is engaged in the development, manufacture, and sale of its Omnipod Insulin Management System, a competitor in the insulin delivery space.
Dexcom
DXCM
Mkt Cap29.08B
DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems for diabetes management, indirectly competing by offering alternative diabetes management solutions.

About

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Show more...
CEO
Mr. Nadav Kidron Esq.
Employees
13
Country
United States
ISIN
US68403P2039

Listings

MU
DE
OJU1.MU
STU
DE
OJU1.STU
TA
IL
ORMP.TA
XNAS
US
ORMP

0 Comments

Share your thoughts

FAQ

What is Oramed Pharmaceuticals stock price today?▼
The current price of ORMP is $3.83 USD — it has decreased by -1.03% in the past 24 hours. Watch Oramed Pharmaceuticals stock price performance more closely on the chart.
What is Oramed Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oramed Pharmaceuticals stocks are traded under the ticker ORMP.
Is Oramed Pharmaceuticals stock price growing?▼
ORMP stock has risen by +5.49% compared to the previous week, the month change is a -17.24% fall, over the last year Oramed Pharmaceuticals has showed a +81.13% increase.
What is Oramed Pharmaceuticals market cap?▼
Today Oramed Pharmaceuticals has the market capitalization of 152.44M
When is the next Oramed Pharmaceuticals earnings date?▼
Oramed Pharmaceuticals is going to release the next earnings report on August 12, 2026.
What were Oramed Pharmaceuticals earnings last quarter?▼
ORMP earnings for the last quarter are 0.12 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oramed Pharmaceuticals revenue for the last year?▼
Oramed Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Oramed Pharmaceuticals net income for the last year?▼
ORMP net income for the last year is -38.12M USD.
Does Oramed Pharmaceuticals pay dividends?▼
Yes, ORMP dividends are paid annual. The last dividend per share was 0.25 USD. As of today, Dividend Yield (FWD)% is 6.46%.
How many employees does Oramed Pharmaceuticals have?▼
As of June 15, 2026, the company has 13 employees.
In which sector is Oramed Pharmaceuticals located?▼
Oramed Pharmaceuticals operates in the Health & Wellness sector.
When did Oramed Pharmaceuticals complete a stock split?▼
The last stock split for Oramed Pharmaceuticals was on January 23, 2013 with a ratio of 1:12.
Where is Oramed Pharmaceuticals headquartered?▼
Oramed Pharmaceuticals is headquartered in New York, United States.